J&J seeks FDA green light for new use of Nucynta XR tablets; Depomed reports $8.6M loss in 3Q;

> West ($WST), a maker of products for injected drugs, has teamed up drug-delivery specialist Vetter to make filled Daikyo Crystal Zenith syringes. Release

> Johnson & Johnson ($JNJ) has asked the FDA to approved its extended-release Nucynta (tapentadol) tablets for pain from diabetic peripheral neuropathy. Release

> Depomed ($DEPO), a developer and provider of extended-release drugs, reported a net loss of $8.6 million in the third quarter, compared with net income of $1.9 million for the same period last year. Release

> Oxford Pharmascience, a developer of new formulations of generic drugs, has raised more than £1.1 million to fund its programs and its business in Brazil. Article

> Halozyme ($HALO) provided upbeat data from an early trial of its fast-acting drug tech used with insulin in patients with type 1 diabetes. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.